author-photo

Christopher Harbison

Bristol-Myers Squibb

59

Papers

10261

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

1302TiPCA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2018 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (205)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (264)
1135PDCharacterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Association of HER2 and IGF1 germline polymorphisms with outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR) with or without cetuximab (CB): The EPIC experience.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (50)
Nivolumab (N)± Ipilimumab (I) bei Patienten mit fortgeschrittenem/metastasiertem chemotherapie-refraktärem (CTx-R) Magenkrebs (G), Speiseröhrenkrebs (E) oder Adenokarzinom des ösophagogastralen Übergangs (GEJ): CheckMate 032 Studie

2017 Viszeralmedizin
Show All
- Source
- Cite
- Save
Citations (0)
674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (61)
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (16)